Reading Hospital/McGlinn Cancer Institute

West Reading, Pennsylvania 19611

2 studies enrolling now · 9 studies all time

What they study most

HER2-Positive Primary Breast Cancer, KRAS G12C Lung Cancer, Leukemia, Myeloid, Acute, Metastatic Breast Cancer, Multiple Myeloma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, Pancreatic Cancer Non-resectable, Primary Myelofibrosis, Refractory Diffuse Large B-cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma, Residual Invasive Breast Cancer

Studies at this site

• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
• DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma — Recruiting now
• A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant — Completed
• Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Connect® Myeloid Disease Registry — Stopped early
• Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer — Completed
• A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer — Stopped early
• Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC — Stopped early